Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib in FGFR-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
NCT05948475Phase 3Active, not recruiting
- Sponsor
- TransThera Biosciences
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of tinengotinib in cholangiocarcinoma (CCA), sponsored by TransThera Biosciences. Started Dec 2023; status: active, not recruiting.
02
Drugs
tinengotinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05948475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948475.